Last reviewed · How we verify
Progestin Only Contraceptive Pills
At a glance
| Generic name | Progestin Only Contraceptive Pills |
|---|---|
| Also known as | Slynd, Camila, Micronor, Errin |
| Sponsor | University of California, San Diego |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Ovulation Incidence in Oral Contraceptive Users (PHASE3)
- Evaluation of Anterior Tibial Knee Translation in Healthy Women With and Without Hormone Therapy (NA)
- Treatment of Prolonged Uterine Bleeding of Etonogestrel (ENG)-Releasing Implant (PHASE4)
- Progestin-Only Pill Use and Breastfeeding Study (PHASE4)
- Assessment of Contraceptive Safety and Effectiveness in Cystic Fibrosis
- Treat of Functional Ovarian Cysts by Compare Between Cocs and Progesterone Only Pills (PHASE3)
- Progestin Primed Double Stimulation Protocol Versus Flexible GnRH Antagonist Protocol in Poor Responders (PHASE3)
- Abnormal Uterine Bleeding and Progestin-only Contraceptives
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: